<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903212</url>
  </required_header>
  <id_info>
    <org_study_id>P/2013/196</org_study_id>
    <nct_id>NCT02903212</nct_id>
  </id_info>
  <brief_title>Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis</brief_title>
  <acronym>APO-RA</acronym>
  <official_title>Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the tolerance of apoptotic autologous cells injection in
      subjects with active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of apoptotic cells injection</measure>
    <time_frame>12 weeks</time_frame>
    <description>Side effects are taken into account to assess tolerance.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous apoptotic cells injection</intervention_name>
    <description>cells injection</description>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of Rheumatoid arthritis

          -  Therapy failure with at least one biological agent from anti-TNF-alpha (etanercept,
             infliximab, adalimumab, certolizumab and golimumab; 3 months at optimal dose),
             anti-IL6 (tocilizumab; 3 months); T-cell costimulatory pathway inhibitor (abatacept; 3
             months); anti-CD20 (rituximab; 6 months at optimal dose); Anti IL-1 (anakinra; 3
             months)

          -  Disease Activity Score (DAS) DAS28 â‰¥ 3.2

          -  Subject has provided written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Inflammatory arthritis other than rheumatoid arthritis

          -  History of invasive cancer

          -  Immunodeficiency (HIV infection, Immunosuppressive therapy)

          -  Active bacterial or viral infections, in particular HCV or HBV.

          -  Surgery not older than 4 weeks.

          -  Unstable comorbidities: uncontrolled diabetes, heart disease, advanced renal or
             hepatic impairment.

          -  Contraindication to an apheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Toussirot, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>etoussirot@chu-besancon.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Toussirot, Professor</last_name>
    <email>etoussirot@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Robert</last_name>
    <phone>0381219086</phone>
    <email>e1robert@chu-besancon.fr</email>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apoptotic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

